The formulation carried an anti-TNFα antibody (Infliximab) and was tested in the gastrointestinal simulation system; this study proved that the COLOPULSE system was able to release the drug at the selected pH, and the authors suggest its possible therapeutic use for ileo-colonic IBD patients [164]. This evidence concerns the gene TNF and inflammatory bowel disease.